HKU Scholars Hub: Browsing DSpace

Browsing by Author Yeo, W

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 20 of 33 next >

Title	Author(s)	Issue Date
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma Journal:Clinical Cancer Research	Lim, HY Heo, J Choi, HJ Lin, CY Yoon, JH Hsu, C Rau, KM Poon, RTP Yeo, W	2014
Adjuvant S-1 chemotherapy after curative resection of gastric cancer Journal:Hong Kong Medical Journal	Yeo, W Lam, KO Law, AL Chiang, CL Lee, CC Au, KH	2017
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors Journal:Hong Kong Medical Journal	Yeo, W Lam, KO Law, LYA Lee, CCY Chiang, CL Au, KH Mo, KF So, TH Lam, KC Ng, WT Li, L	2017
Change patterns in supportive care needs among women diagnosed with advanced breast cancer Proceeding/Conference:Hong Kong International Cancer Congress, HKICC 2011	Au, HYA Lam, WWT Tsang, JWH Yau, TK Soong, I Yeo, W Suen, J Ho, WM Wong, KY Kwong, A Suen, DTK Sze, WK Ng, A Girgis, A Fielding, R	2011
Comparing the meanings of living with advanced breast cancer between women resilient to distress and women with persistent distress: a qualitative study Journal:Psycho-Oncology	Lam, WWT Yoon, SW Sze, WK Ng, AW Soong, I Kwong, A Suen, TKD Tsang, JJ Yeo, W Wong, KY Fielding, R	2016
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population Journal:JNCI: Journal of the National Cancer Institute	Lin, CH Yap, YS Lee, KH Im, SA Naito, Y Yeo, W Ueno, T Kwong, A Li, H Huang, SM Leung, R Han, W Tan, B Hu, FC Huang, CS Cheng, AL Lu, YS	2019
Costs and benefits of dose-dense chemotherapy scheduling in Hong Kong Chinese patients with primary breast cancer Proceeding/Conference:ASCO Annual Meeting Proceedings	Tsang, J Yau, T Chan, ATC Liang, RHS Yeo, W Epstein, R	2007
Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas Journal:Oncogene	Jin, H Wang, X Ying, J Wong, AHY Li, H Lee, KY Srivastava, G Chan, ATC Yeo, W Ma, BBY Putti, TC Lung, ML Shen, ZY Xu, LY Langford, C Tao, Q	2007
The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors Journal:PLoS ONE	Shu, XS Geng, H Li, L Ying, J Ma, C Wang, Y Poon, FF Wang, X Ying, Y Yeo, W Srivastava, G Tsao, SW Yu, J Sung, JJY Huang, S Chan, ATC Tao, Q	2011
Erratum: Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma (Future Oncology (2011) 7:10 (1149-1167)) Journal:Future Oncology	Zhou, Q Lui, VWY Yeo, W	2012
The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study Journal:Psycho-oncology	Lam, WWT Soong, I Yau, TK Wong, KY Tsang, JWH Yeo, W Suen, J Ho, WM Sze, WK Ng, AW Kwong, A Suen, TKD Fielding, R	2013
The evolution of supportive care needs trajectories in women with advanced breast cancer during the 12 months following diagnosis Journal:Supportive Care in Cancer	Lam, WWT Tsang, JWH Yeo, W Suen, J Ho, WM Yau, TK Soong, I Wong, KY Kwong, A Suen, TKD Sze, WK Ng, WY Girgis, A Fielding, R	2014
Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study Journal:BMC Cancer	Lam, WWT Kwong, A Suen, TKD Tsang, WHJ Soong, I Yau, TK Yeo, W Suen, J Ho, WM Wong, KY Sze, WK Ng, AWY Fielding, R	2018
Goal adjustment influence on psychological well-being following advanced breast cancer diagnosis Journal:Psycho-Oncology	Lam, WWT Yeo, W Suen, J Ho, WM Tsang, JWH Soong, SI Yau, TK Wong, KY Sze, WK Ng, AW	2016
Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis From the CheckMate 040 Study Journal:Journal of Hepatology	Yau, TCC Hsu, C Kim, TY Choo, S Kang, YK Hou, MM Numata, K Yeo, W Chopra, A Ikeda, M Kuromatsu, R Moriguchi, M	2019
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Journal:Lancet	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Kudo, M Hsu, C Kim, TY Choo, SP Trojan, J Welling, TH Meyer, T Kang, YK Yeo, W Chopra, A Anderson, J Dela Cruz, C Lang, L Neely, J Tang, H Dastani, HB Melero, I	2017
Patterns of psychological distress among Chinese women diagnosed with advanced breast cancer Proceeding/Conference:IPOS / COSA 2012	Lam, WWT Ng, J Tsang, J Yau, TK Soong, I Yeo, W Suen, J Ho, WM Wong, KY Kwong, A Suen, D Sze, WK Ng, A Fielding, R	2012
Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma Proceeding/Conference:Annals of Oncology	Loong, H Yuen, C Mo, F Chan, TC Lee, KWC Chan, ACY Wong, ACY Wong, KCW Lam, CM Tong, J Wong, CKH Yeo, W	2017
Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the CheckMate 040 Dose-Escalation Study Proceeding/Conference:Liver Cancer	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Welling, TH, III Yeo, W Chopra, A Anderson, J dela Cruz, C Lang, L Neely, J Melero, I	2016
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research	Lim, HY Merle, P Weiss, KH Yau, TCC Ross, P Mazzaferro, V Blanc, JF Ma, YT Yen, CJ Kocsis, J Choo, SP Sukeepaisarnjaroen, W Gérolami, R Dufour, JF Gane, EJ Ryoo, BY Peck-Radosavljevic, M Dao, T Yeo, W Lamlertthon, W Thongsawat, S Teufel, M Roth, K Reis, D Childs, BH Krissel, H Llovet, JM	2018

Showing results 1 to 20 of 33 next >